重庆医学2012，Vol.41Issue(1)：44-46,3.DOI:10.3969/j.issn.1671-8348.2012.01.017
培美曲塞联合铂类治疗非小细胞肺癌的Meta分析
Pemetrexed plus platinum in non-small cell lung cancer:a Meta analysis of randomized controlled trials
陶玲 1卓文磊 1杨帆 1朱波1
作者信息
- 1. 第三军医大学新桥医院全军肿瘤研究所,重庆,400037
- 折叠
摘要
Abstract
Objective To observe the efficacy and toxicity of pemetrexed plus platinum versus gemcitabine plus platinum with advanced NSCLC. Methods Articles were selected from PubMed,Medline, Embase, VIP,CBM,CNKI, the Cochrane library. Meta-analysis was completed using software Review Manager 4. 2. Results Meta analysis results suggested that; COMPARED with gecitabine plus platinum chemotherapy, pemetrexed plus platinum had no statistically significant benefit in 1-year survival rate, while Pemetrexed plus platinum had less hematologic toxicity. Including; Neutropenia, Anemia, Thrombocytopenia, Leukopeniao The two chemotherapies were similar toxicity in non-hematology. Conclusion Pemetrexed plus platinum provides similar survival when compared with gecitabine plus platinum with less hematologic toxicity.关键词
癌,非小细胞肺/培美曲塞/吉西他滨/Meta分析Key words
carcinoma, non-small cell lung/ pemetrexed / gemcitabine/ Meta-analysis引用本文复制引用
陶玲,卓文磊,杨帆,朱波..培美曲塞联合铂类治疗非小细胞肺癌的Meta分析[J].重庆医学,2012,41(1):44-46,3.
